Work

PS5-09-22: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer

Year: 2026

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-09-22

Authors: S. Damodaran, A. N. Marx, T. Iwase, Y. Yuan, M. Kai, J. Lee, C. H. Barcenas, N. T. Ueno

Institutions: The University of Texas MD Anderson Cancer Center, University of Hawaii Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129655479

FWCI:

Cites:

Cited by:

Related to: